Position in JAZZ
as of Jun 30, 2026
· filed Jul 7, 2026
Position Value
$3,855
+$2,772 QoQ
Shares Held
16
+77.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#592
of 640 holders
Holding Since
Dec 2021
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JAZZ Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Byrne Asset Management LLC holds $220,999 across 8 Biotechnology names. JAZZ ranks #6 (1.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CRVO |
CervoMed Inc.
|
51,250 | $158,875 | |
| 2 | EXEL |
Exelixis, Inc.
|
357 | $19,424 | |
| 3 | INCY |
Incyte Corp
|
165 | $18,704 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22 | $13,717 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
80 | $6,261 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
This page
|
16 | $3,855 | |
| 7 | AUTL |
Autolus Therapeutics plc
|
100 | $160 | |
| 8 | ELDN |
Eledon Pharmaceuticals, Inc.
|
1 | $3 |
All Filings in JAZZ
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,855 | 16 | Shares | Sole | 2026-07-07 | |
| 2024-03-31 | $1,083 | 9 | Shares | Sole | 2024-04-22 | |
| 2023-12-31 | $3,813 | 31 | Shares | Sole | 2024-01-29 | |
| 2023-09-30 | $5,954 | 46 | Shares | Sole | 2023-10-31 | |
| 2023-06-30 | $5,702 | 46 | Shares | Sole | 2023-07-21 | |
| 2023-03-31 | $6,731 | 46 | Shares | Sole | 2023-04-17 | |
| 2022-12-31 | $7,328 | 46 | Shares | Sole | 2023-01-30 | |
| 2022-09-30 | $7,464 | 56 | Shares | Sole | 2022-10-19 | |
| 2022-06-30 | $16,537 | 106 | Shares | Sole | 2022-07-20 | |
| 2022-03-31 | $28,020 | 180 | Shares | Sole | 2022-04-05 | |
| 2021-12-31 | $22,932 | 180 | Shares | Sole | 2022-02-22 | |
| No filing history on record for this holder in this stock. | ||||||